Radiation Therapy with or without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeTrial IDs
Phase IIISupportive care, TreatmentActive18 and overRTOG-0920
NCI-2011-00878, CDR0000651536, NCT01311063, NCT00956007

Trial Description

Summary

This randomized phase III trial studies radiation therapy alone to see how well it works compared with radiation therapy and cetuximab in treating patients who have undergone surgery for head and neck cancer that has spread to nearby tissues or organs. Radiation therapy uses high-energy x-rays to kill tumor cells. Using a 3-dimensional (3-D) image of the tumor to help focus the radiation directly onto the tumor, and giving the radiation in higher doses over a shorter period of time, may kill more tumor cells and cause fewer side effects. Monoclonal antibodies, such as cetuximab, may block tumor growth by targeting certain cells. It is not yet known whether radiation therapy is more effective when given alone or together with cetuximab in treating patients with head and neck cancer that has been removed by surgery.

Further Study Information

PRIMARY OBJECTIVES:

I. Test whether the addition of cetuximab to radiation therapy will improve overall survival (OS) in postoperative patients with intermediate risk following surgery.

SECONDARY OBJECTIVES:

I. Assess the impact of the addition of cetuximab to postoperative radiation therapy on disease-free survival (DFS).

II. Assess the impact of the addition of cetuximab to postoperative radiation therapy on acute dysphagia, dry mouth, skin toxicity, and other toxicities (Common Terminology Criteria for Adverse Events [CTCAE], version [v.] 4) and their relationships to patient-reported outcomes at 3 months.

III. Assess the impact of the addition of cetuximab to postoperative radiation therapy on late dysphagia, dry mouth, skin toxicity, and other toxicities (CTCAE, v. 4) and their relationships to patient-reported outcomes at 12 and 24 months.

IV. Tumor analysis of epidermal growth factor receptor (EGFR), specifically extent of EGFR overexpression by immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) analysis, EGFR variant III (EGFRvIII) expression, as well as association of these assay data with OS and DFS.

V. Tumor analysis of human papillomavirus (HPV) infection (as defined by in situ hybridization), specifically, within the cohort of patients with oropharynx cancer, to perform an exploratory analysis of the impact of HPV on DFS and OS in this patient subset.

VI. Tumor deoxyribonucleic acid (DNA) analyses of tumor protein 53 (TP53) mutations for response prediction to cetuximab and prognosis.

VII. Germline DNA analyses of polymorphic variants in EGFR intron repeats for response prediction to cetuximab.

TERTIARY OBJECTIVES:

I. Assess the impact of the addition of cetuximab to postoperative radiation therapy on local-regional control.

II. Assess the impact of the addition of cetuximab to postoperative radiation therapy on patient-reported quality of life (QOL), swallowing, xerostomia, and skin toxicity based on head and neck specific instruments, including the Performance Status Scale for Head and Neck Cancer (PSS-HN), the Functional Assessment of Cancer Therapy-Head & Neck (FACT-H&N), the University of Michigan Xerostomia-Related Quality of Life Scale (XeQOLS), and the Dermatology Life Quality Index (DLQI).

III. Assess the impact of the addition of cetuximab to postoperative radiation therapy on cost-utility analysis using the EuroQol (EQ-5D).

IV. To evaluate the utility of image-guided radiotherapy (IGRT) as a means of enhancing the efficacy (i.e., local-regional control) of intensity-modulated radiation therapy (IMRT) while reducing the acute and/or late toxicity (particularly xerostomia) and improving patient-reported outcomes (particularly XeQOLS scores).

V. To retrospectively compare the local regional control rate for patients treated with IMRT alone (no IGRT or cetuximab) with similar patients treated with external beam radiotherapy alone in the postoperative trial Radiation Therapy Oncology Group (RTOG) 95-01.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients undergo IMRT once daily (QD) for a total of 30 fractions in the absence of disease progression or unacceptable toxicity.

ARM II: Patients undergo IMRT as in arm I. Patients also receive cetuximab intravenously (IV) over 60-120 minutes once weekly beginning at least 5 days prior to the start of IMRT for 11 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1 and 3 months, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Eligibility Criteria

Inclusion Criteria:

Pathologically (histologically) proven diagnosis of squamous cell carcinoma (including variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma not otherwise specified [NOS], etc.) of the head/neck (oral cavity, oropharynx or larynx); note: hypopharynx primaries are excluded

Clinical stage T1, N1-2 or T2-4a, N0-2, M0 including no distant metastases, based upon the following minimum diagnostic workup:

General history and physical examination by a radiation oncologist and/or medical oncologist within 8 weeks prior to registration

Examination by an ear, nose and throat (ENT) or head & neck surgeon, within 8 weeks prior to registration; a laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) is recommended but not required

Chest x-ray (at a minimum) or chest computed tomography (CT) scan (with or without contrast) or CT/positron emission tomography (PET) of chest (with or without contrast) within 8 weeks prior to registration

Gross total resection of the primary tumor with curative intent must be completed within 7 weeks of registration with surgical pathology demonstrating one or more of the following “intermediate” risk factors:

Perineural invasion

Lymphovascular invasion

Single lymph node > 3 cm or >= 2 lymph nodes (all < 6 cm) (no extracapsular extension)

Close margin(s) of resection, defined as cancer extending to within 5 mm of a surgical margin, and/or an initially focally positive margin that is subsequently superseded by intraoperative negative margins; similarly, patients whose tumors had focally positive margins in the main specimen but negative margins from re-excised samples in the region of the positive margin are eligible; for questions or ambiguities about an individual case, contact Dr. Machtay and/or Dr. Holsinger prior to enrolling the patient

Pathologically confirmed T3 or T4a primary tumor; for questions or ambiguities about an individual case, contact Dr. Machtay and/or Dr. Holsinger prior to enrolling the patient

T2 oral cavity cancer with > 5 mm depth of invasion

Zubrod performance status 0-1

Absolute granulocyte count (AGC) >= 1,500/mm³

Platelet count >= 100,000/mm³

Hemoglobin >= 8.0 g/dL (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)

Total bilirubin < 2 x institutional upper limit of normal (ULN)

Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x institutional ULN

Serum creatinine < 2 x institutional ULN or; creatinine clearance (CC) >= 50 mL/min determined by 24-hour collection or estimated by Cockcroft-Gault formula

Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential

The following assessments are required within 2 weeks prior to the start of registration: sodium (Na), potassium (K), chloride (Cl), glucose, calcium (Ca), magnesium (Mg), and albumin; note: patients with an initial magnesium < 0.5 mmol/L (1.2 mg/dl) may receive corrective magnesium supplementation but should continue to receive either prophylactic weekly infusion of magnesium and/or oral magnesium supplementation (e.g., magnesium oxide) at the investigator’s discretion

Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control

Patients must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for EGFR and for oropharyngeal patients, HPV analyses

Exclusion Criteria:

Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; noninvasive cancers (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated < 3 years ago; patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with primary tumor (T)1-2, nearby lymph nodes (N)0, metastasis (M)0 resected differentiated thyroid carcinoma, who are eligible

Per the operative and/or pathology report, positive margin(s) (defined as tumor present at the cut or inked edge of the tumor), nodal extracapsular extension, and/or gross residual disease after surgery; note: patients whose tumors had focally positive margins in the main specimen but negative margins from re-excised samples in the region of the positive margin are eligible; for questions or ambiguities about an individual case, contact Dr. Machtay and/or Dr. Holsinger prior to enrolling the patient

Prior systemic chemotherapy or anti-EGF therapy for the study cancer; note: prior chemotherapy or anti-EGF therapy for a different cancer is allowable

Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields

Severe, active co-morbidity, defined as follows:

Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to registration

Transmural myocardial infarction within 6 months prior to registration

Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration

Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration

Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to registration

Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol

Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients

Grade 3-4 electrolyte abnormalities (CTCAE, v. 4):

  • Serum calcium (ionized or adjusted for albumin) < 7 mg/dl (1.75 mmol/L) or > 12.5 mg/dl (> 3.1 mmol/L) despite intervention to normalize levels
  • Glucose < 40 mg/dl (< 2.2 mmol/L) or > 250 mg/dl (> 14 mmol/L)
  • Magnesium < 0.9 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels
  • Potassium < 3.0 mmol/L or > 6 mmol/L despite intervention to normalize levels
  • Sodium < 130 mmol/L or > 155 mmol/L despite intervention to normalize levels

Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception

Prior allergic reaction to cetuximab

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

NRG Oncology

  • National Cancer Institute
Mitchell Machtay, Principal Investigator

Trial Sites

U.S.A.

Alabama
Birmingham

University of Alabama at Birmingham Cancer Center

Sharon A. Spencer
Ph: 205-934-0309

Sharon A. Spencer
Principal Investigator

Alaska
Anchorage

Providence Alaska Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Arizona
Tucson

Arizona Oncology Associates-West Orange Grove

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

California
Auburn

Sutter Cancer Centers Radiation Oncology Services-Auburn

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Cameron Park

Sutter Cancer Centers Radiation Oncology Services-Cameron Park

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Fresno

Fresno Cancer Center

Samantha Andrews Seaward
Ph: 408-851-8010
Email: samantha.seaward@kp.org

Samantha Andrews Seaward
Principal Investigator

La Jolla

UC San Diego Moores Cancer Center

Loren K. Mell
Ph: 858-822-5354
Email: cancercto@ucsd.edu

Loren K. Mell
Principal Investigator

Los Angeles

Kaiser Permanente Los Angeles Medical Center

Michael Raymond Girvigian
Ph: 626-564-3455

Michael Raymond Girvigian
Principal Investigator

Los Angeles County-USC Medical Center

Eugene I. Chung
Ph: 323-865-0451

Eugene I. Chung
Principal Investigator

USC / Norris Comprehensive Cancer Center

Eugene I. Chung
Ph: 323-865-0451

Eugene I. Chung
Principal Investigator

Modesto

Memorial Medical Center

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Oakland

Kaiser Permanente Oakland-Broadway

Samantha Andrews Seaward
Ph: 408-851-8010
Email: samantha.seaward@kp.org

Samantha Andrews Seaward
Principal Investigator

Orange

UC Irvine Health/Chao Family Comprehensive Cancer Center

Chaitali S. Nangia
Ph: 877-827-8839
Email: ucstudy@uci.edu

Chaitali S. Nangia
Principal Investigator

Pomona

Pomona Valley Hospital Medical Center

Yallapragada S. (Ram) Rao
Ph: 909-865-9555

Yallapragada S. (Ram) Rao
Principal Investigator

Rancho Cordova

Kaiser Permanente-Rancho Cordova Cancer Center

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Roseville

Sutter Cancer Centers Radiation Oncology Services-Roseville

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

The Permanente Medical Group-Roseville Radiation Oncology

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

Sacramento

Sutter General Hospital

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

University of California Davis Comprehensive Cancer Center

Shyam S. D. Rao
Ph: 916-734-3089

Shyam S. D. Rao
Principal Investigator

Saint Helena

Saint Helena Hospital

David John Tate
Ph: 707-967-3698

David John Tate
Principal Investigator

Santa Clara

Kaiser Permanente Medical Center - Santa Clara

Samantha Andrews Seaward
Ph: 626-564-3455

Samantha Andrews Seaward
Principal Investigator

South San Francisco

Kaiser Permanente Cancer Treatment Center

Samantha Andrews Seaward
Ph: 408-851-8010
Email: samantha.seaward@kp.org

Samantha Andrews Seaward
Principal Investigator

Vacaville

Sutter Cancer Centers Radiation Oncology Services-Vacaville

Christopher Uwe Jones
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Christopher Uwe Jones
Principal Investigator

Colorado
Aurora

Rocky Mountain Cancer Centers-Aurora

Keren Sturtz
Ph: 303-777-2642
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

University of Colorado Cancer Center - Anschutz Cancer Pavilion

Sana Dole Karam
Ph: 720-848-0650

Sana Dole Karam
Principal Investigator

Colorado Springs

Penrose-Saint Francis Healthcare

Keren Sturtz
Ph: 303-777-2642
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Denver

Porter Adventist Hospital

Keren Sturtz
Ph: 303-777-2642
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Englewood

Swedish Medical Center

Keren Sturtz
Ph: 303-777-2642
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Littleton

Rocky Mountain Cancer Centers-Littleton

Keren Sturtz
Ph: 303-777-2642
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Loveland

McKee Medical Center

Keren Sturtz
Ph: 303-777-2642
Email: kgeisen@co-cancerresearch.org

Keren Sturtz
Principal Investigator

Connecticut
Bridgeport

Saint Vincent's Medical Center

Christopher Michael Iannuzzi
Ph: 203-576-6329
Email: twhite@stvincents.org

Christopher Michael Iannuzzi
Principal Investigator

Hartford

Hartford Hospital

Neal B. Goldberg
Ph: 860-224-5660

Neal B. Goldberg
Principal Investigator

New Britain

The Hospital of Central Connecticut

Neal B. Goldberg
Ph: 860-224-5660

Neal B. Goldberg
Principal Investigator

New Haven

Yale University

Zain A. Husain
Ph: 203-785-5702

Zain A. Husain
Principal Investigator

Delaware
Newark

Christiana Care Health System-Christiana Hospital

Adam Raben
Ph: 302-733-6227

Adam Raben
Principal Investigator

Florida
Orlando

UF Cancer Center at Orlando Health

Rafael Ricardo Manon
Ph: 321-841-7246
Email: CancerClinicalTrials@orlandohealth.com

Rafael Ricardo Manon
Principal Investigator

Georgia
Atlanta

Emory University/Winship Cancer Institute

Jonathan Jay Beitler
Ph: 404-778-4139
Email: jjbeitl@emory.edu

Jonathan Jay Beitler
Principal Investigator

Grady Health System

Jonathan Jay Beitler
Ph: 404-778-4139
Email: jjbeitl@emory.edu

Jonathan Jay Beitler
Principal Investigator

Gainesville

Northeast Georgia Medical Center

Frank Greer Lake
Ph: 770-219-8800
Email: cancerpatient.navigator@nghs.com

Frank Greer Lake
Principal Investigator

Savannah

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

John A. Pablo
Ph: 800-622-6877

John A. Pablo
Principal Investigator

Memorial University Medical Center

Aaron Watson Pederson
Ph: 912-350-8568

Aaron Watson Pederson
Principal Investigator

Hawaii
Honolulu

Queen's Medical Center

Richard Y. Lee
Ph: 808-547-6583
Email: rlee@tccoh.com

Richard Y. Lee
Principal Investigator

The Cancer Center of Hawaii-Liliha

Richard Y. Lee
Ph: 808-547-6583
Email: rlee@tccoh.com

Richard Y. Lee
Principal Investigator

University of Hawaii Cancer Center

Richard Y. Lee
Ph: 808-547-6583
Email: rlee@tccoh.com

Richard Y. Lee
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Illinois
Chicago

John H Stroger Jr Hospital of Cook County

Thomas E. Lad
Ph: 312-864-6000

Thomas E. Lad
Principal Investigator

Decatur

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Harvey

Ingalls Memorial Hospital

Sulochana D. Yalavarthi
Ph: 708-915-4673
Email: clinicaltrials@ingalls.org

Sulochana D. Yalavarthi
Principal Investigator

Hines

Hines Veterans Administration Hospital

Cheryl M. Czerlanis
Ph: 708-226-4357

Cheryl M. Czerlanis
Principal Investigator

Joliet

Joliet Oncology-Hematology Associates Limited

Jason Jung-Gon Suh
Ph: 815-725-1621
Email: maureenc@jolietoncology.com

Jason Jung-Gon Suh
Principal Investigator

Maywood

Loyola University Medical Center

Bahman Emami
Ph: 708-226-4357

Bahman Emami
Principal Investigator

Pekin

OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peoria

Methodist Medical Center of Illinois

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

OSF Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

OSF Saint Francis Radiation Oncology at Peoria Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peru

Valley Radiation Oncology

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Rockford

SwedishAmerican Regional Cancer Center/ACT

Harvey E. Einhorn
Ph: 779-696-9400
Email: cancercare@swedishamerican.org

Harvey E. Einhorn
Principal Investigator

Springfield

Memorial Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Saint John's Hospital

Samuel P. Au
Ph: 217-757-6754
Email: diana.weyhenmeyer@st-johns.org

Samuel P. Au
Principal Investigator

Indiana
Bloomington

IU Health Bloomington

Fred Y. Wu
Ph: 812-353-2831

Fred Y. Wu
Principal Investigator

Fort Wayne

Parkview Hospital Randallia

Brian K. Chang
Ph: 260-373-8888
Email: parkviewresearch@parkview.com

Brian K. Chang
Principal Investigator

Radiation Oncology Associates PC

Brian K. Chang
Ph: 260-373-8888
Email: parkviewresearch@parkview.com

Brian K. Chang
Principal Investigator

Indianapolis

Community Hospital East

Shih Jack Wei
Ph: 317-621-4295
Email: swei@ecommunity.com

Shih Jack Wei
Principal Investigator

Community Regional Cancer Care-North

Shih Jack Wei
Ph: 317-621-4295
Email: swei@ecommunity.com

Shih Jack Wei
Principal Investigator

IU Health Methodist Hospital

Alexander M. Yeh
Ph: 765-646-8358

Alexander M. Yeh
Principal Investigator

South Bend

Memorial Hospital of South Bend

David Alan Hornback
Ph: 574-647-3148
Email: dhornback@beaconhealthsystem.org

David Alan Hornback
Principal Investigator

Iowa
Ames

McFarland Clinic PC-William R Bliss Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Des Moines

Iowa Methodist Medical Center

Robert J. Behrens
Ph: 515-282-2921

Robert J. Behrens
Principal Investigator

Mercy Medical Center - Des Moines

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Kansas
Kansas City

University of Kansas Cancer Center

Parvesh Kumar
Ph: 913-588-3663
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Overland Park

The University of Kansas Cancer Center-Overland Park

Parvesh Kumar
Ph: 913-588-3663
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Kentucky
Owensboro

Owensboro Health Mitchell Memorial Cancer Center

Ryan Jared Abel
Ph: 270-688-3691
Email: shawns@omhs.org

Ryan Jared Abel
Principal Investigator

Louisiana
Baton Rouge

Mary Bird Perkins Cancer Center

Augusto C. Ochoa
Ph: 504-568-2428
Email: emede1@lsuhsc.edu

Augusto C. Ochoa
Principal Investigator

New Orleans

Louisiana State University Health Science Center

Mitchell Machtay
Ph: 800-641-2422
Email: mitchell.machtay@uhhospitals.org

Mitchell Machtay
Principal Investigator

Touro Infirmary

Augusto C. Ochoa
Ph: 504-568-2428
Email: emede1@lsuhsc.edu

Augusto C. Ochoa
Principal Investigator

Tulane University Health Sciences Center

William Russell Robinson
Ph: 504-988-6121

William Russell Robinson
Principal Investigator

Maryland
Baltimore

Greater Baltimore Medical Center

Marshall A. Levine
Ph: 443-849-3706

Marshall A. Levine
Principal Investigator

University of Maryland/Greenebaum Cancer Center

Mohan Suntharalingam
Ph: 800-888-8823

Mohan Suntharalingam
Principal Investigator

Bel Air

Upper Chesapeake Medical Center

Mohan Suntharalingam
Ph: 800-888-8823

Mohan Suntharalingam
Principal Investigator

Salisbury

Peninsula Regional Medical Center

John Romeo Mansueti
Ph: 866-922-6237

John Romeo Mansueti
Principal Investigator

Massachusetts
Boston

Boston Medical Center

Minh Tam Truong
Ph: 617-638-8265

Minh Tam Truong
Principal Investigator

Burlington

Lahey Hospital and Medical Center

Francis Warren Nugent
Ph: 781-744-8027

Francis Warren Nugent
Principal Investigator

Pittsfield

Berkshire Hematology Oncology PC

Harvey Zimbler
Ph: 413-496-8205
Email: ggero@bhs1.org

Harvey Zimbler
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Bay City

McLaren-Bay Region

Kiran Devisetty
Ph: 989-667-6257

Kiran Devisetty
Principal Investigator

Dearborn

Oakwood Hospital and Medical Center

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Detroit

Saint John Hospital and Medical Center

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Flint

McLaren Cancer Institute-Flint

Kiran Devisetty
Ph: 989-667-6257

Kiran Devisetty
Principal Investigator

Kalamazoo

West Michigan Cancer Center

Kathleen J. Yost
Ph: 616-391-1230
Email: connie.szczepanek@grcop.org

Kathleen J. Yost
Principal Investigator

Lapeer

McLaren Cancer Institute-Lapeer Region

Kiran Devisetty
Ph: 989-667-6257

Kiran Devisetty
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Mount Pleasant

McLaren Cancer Institute-Central Michigan

Kiran Devisetty
Ph: 989-667-6257

Kiran Devisetty
Principal Investigator

Owosso

McLaren Cancer Institute-Owosso

Kiran Devisetty
Ph: 989-667-6257

Kiran Devisetty
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Royal Oak

William Beaumont Hospital-Royal Oak

Daniel J. Krauss
Ph: 248-551-7695

Daniel J. Krauss
Principal Investigator

Saginaw

Saint Mary's of Michigan

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Troy

William Beaumont Hospital - Troy

Daniel J. Krauss
Ph: 248-551-7695

Daniel J. Krauss
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Samir Narayan
Ph: 734-712-4673

Samir Narayan
Principal Investigator

Minnesota
Duluth

Saint Luke's Hospital of Duluth

Steven R. Bonin
Ph: 218-249-7888
Email: kdean@slhduluth.com

Steven R. Bonin
Principal Investigator

Mississippi
Pascagoula

Singing River Hospital

James E. Clarkson
Ph: 228-809-5220
Email: james.clarkson@mysrhs.com

James E. Clarkson
Principal Investigator

Missouri
Cape Girardeau

Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-6606
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Creve Coeur

Barnes-Jewish West County Hospital

Wade L. Thorstad
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Wade L. Thorstad
Principal Investigator

Kansas City

North Kansas City Hospital

Parvesh Kumar
Ph: 913-588-3663
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

The University of Kansas Cancer Center-North

Parvesh Kumar
Ph: 913-588-3663
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Lee's Summit

The University of Kansas Cancer Center-Lee's Summit

Parvesh Kumar
Ph: 913-588-3663
Email: ctnursenav@kumc.edu

Parvesh Kumar
Principal Investigator

Saint Louis

Mercy Hospital Saint Louis

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Missouri Baptist Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Saint Anthony's Medical Center

Minxiang (Michael) Gu
Ph: 888-823-5923
Email: ctsucontact@westat.com

Minxiang (Michael) Gu
Principal Investigator

Washington University School of Medicine

Wade L. Thorstad
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Wade L. Thorstad
Principal Investigator

Saint Peters

Siteman Cancer Center - Saint Peters

Wade L. Thorstad
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Wade L. Thorstad
Principal Investigator

Springfield

CoxHealth South Hospital

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Mercy Hospital Springfield

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Montana
Billings

Billings Clinic Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274
Email: bmarchello@mtcancer.org

Benjamin T. Marchello
Principal Investigator

Nebraska
Lincoln

Saint Elizabeth Regional Medical Center

Mehmet Sitki Copur
Ph: 800-998-2119

Mehmet Sitki Copur
Principal Investigator

Omaha

Nebraska Methodist Hospital

Tien-Shew William Huang
Ph: 402-354-5144

Tien-Shew William Huang
Principal Investigator

University of Nebraska Medical Center

Weining (Ken) Zhen
Ph: 402-559-8555
Email: llarson@unmc.edu

Weining (Ken) Zhen
Principal Investigator

New Hampshire
Exeter

Exeter Hospital

Gary Miller Proulx
Ph: 800-439-3837

Gary Miller Proulx
Principal Investigator

Keene

Cheshire Medical Center-Dartmouth-Hitchcock Keene

Alan Charles Hartford
Ph: 603-650-6616
Email: cancer.research.nurse@dartmouth.edu

Alan Charles Hartford
Principal Investigator

Lebanon

Dartmouth Hitchcock Medical Center

Alan Charles Hartford
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Alan Charles Hartford
Principal Investigator

New Jersey
Mount Holly

Virtua Memorial

Lemuel S. Ariaratnam
Ph: 609-914-6762

Lemuel S. Ariaratnam
Principal Investigator

Princeton

The Medical Center At Princeton

Joseph M. Pepek
Ph: 609-497-4475
Email: jpepek@prapa.com

Joseph M. Pepek
Principal Investigator

Sparta

Sparta Cancer Treatment Center

Rita S. Axelrod
Ph: 215-955-6084

Rita S. Axelrod
Principal Investigator

Voorhees

Virtua Voorhees

Lemuel S. Ariaratnam
Ph: 609-914-6762

Lemuel S. Ariaratnam
Principal Investigator

New Mexico
Albuquerque

University of New Mexico Cancer Center

Benny J. Liem
Ph: 505-272-6972

Benny J. Liem
Principal Investigator

New York
Albany

New York Oncology Hematology PC - Albany

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Brooklyn

Maimonides Medical Center

Jay Scott Cooper
Ph: 718-765-2709
Email: jcooper@maimonidesmed.org

Jay Scott Cooper
Principal Investigator

The New York Methodist Hospital

Krishnamurthi Sundaram
Ph: 718-270-3924
Email: sima.terebelo@downstate.edu

Krishnamurthi Sundaram
Principal Investigator

Canandiaqua

Sands Cancer Center

Yuhchyau Chen
Ph: 585-275-1531
Email: yuhchyau_chen@urmc.rochester.edu

Yuhchyau Chen
Principal Investigator

Elmira

Arnot Ogden Medical Center/Falck Cancer Center

Chi K. Tsang
Ph: 607-271-7000

Chi K. Tsang
Principal Investigator

Glens Falls

Glens Falls Hospital

John Patrick Stoutenburg
Ph: 518-926-6700

John Patrick Stoutenburg
Principal Investigator

Rochester

Highland Hospital

Yuhchyau Chen
Ph: 585-275-5830

Yuhchyau Chen
Principal Investigator

University of Rochester

Yuhchyau Chen
Ph: 585-275-5830

Yuhchyau Chen
Principal Investigator

University Radiation Oncology

Yuhchyau Chen
Ph: 585-275-1531
Email: yuhchyau_chen@urmc.rochester.edu

Yuhchyau Chen
Principal Investigator

Syracuse

State University of New York Upstate Medical University

Seung Shin Hahn
Ph: 315-464-5476

Seung Shin Hahn
Principal Investigator

North Carolina
Asheville

Mission Hospital-Memorial Campus

Christopher H. Chay
Ph: 828-418-0932
Email: chay@ccwnc.com

Christopher H. Chay
Principal Investigator

Chapel Hill

UNC Lineberger Comprehensive Cancer Center

Bhishamjit S. Chera
Ph: 877-668-0683
Email: cancerclinicaltrials@med.unc.edu

Bhishamjit S. Chera
Principal Investigator

Charlotte

Carolinas Medical Center/Levine Cancer Institute

Benjamin James Moeller
Ph: 704-403-1520

Benjamin James Moeller
Principal Investigator

Gastonia

CaroMont Regional Medical Center

Charles J. Meakin
Ph: 704-834-2932

Charles J. Meakin
Principal Investigator

Kinston

Kinston Medical Specialists PA

Peter Robins Watson
Ph: 252-559-2200

Peter Robins Watson
Principal Investigator

Winston-Salem

Wake Forest University Health Sciences

Kathryn McConnell Greven
Ph: 336-713-6771

Kathryn McConnell Greven
Principal Investigator

North Dakota
Bismarck

Sanford Bismarck Medical Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Fargo

Roger Maris Cancer Center

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Grand Forks

Altru Cancer Center

Grant Richard Seeger
Ph: 701-780-6520

Grant Richard Seeger
Principal Investigator

Ohio
Akron

Summa Akron City Hospital/Cooper Cancer Center

Desiree E. Doncals
Ph: 330-375-6101

Desiree E. Doncals
Principal Investigator

Barberton

Summa Barberton Hospital

Desiree E. Doncals
Ph: 330-375-6101

Desiree E. Doncals
Principal Investigator

Beachwood

UHHS-Chagrin Highlands Medical Center

Min Yao
Ph: 800-641-2422

Min Yao
Principal Investigator

Canton

Mercy Medical Center

Edward J. Walsh
Ph: 888-293-4673

Edward J. Walsh
Principal Investigator

Chardon

Geaugra Hospital

Min Yao
Ph: 800-641-2422

Min Yao
Principal Investigator

Cincinnati

University of Cincinnati

Kevin Patrick Redmond
Ph: 513-558-4553
Email: uchealthnews@uc.edu

Kevin Patrick Redmond
Principal Investigator

Cleveland

Case Western Reserve University

Min Yao
Ph: 800-641-2422

Min Yao
Principal Investigator

Cleveland Clinic Cancer Center/Fairview Hospital

David J. Adelstein
Ph: 866-223-8100

David J. Adelstein
Principal Investigator

Cleveland Clinic Foundation

David J. Adelstein
Ph: 866-223-8100

David J. Adelstein
Principal Investigator

Columbus

Ohio State University Comprehensive Cancer Center

Maura Lianne Gillison
Ph: 800-293-5066
Email: Jamesline@osumc.edu

Maura Lianne Gillison
Principal Investigator

Elyria

Mercy Cancer Center-Elyria

Min Yao
Ph: 800-641-2422

Min Yao
Principal Investigator

Independence

Cleveland Clinic Cancer Center Independence

David J. Adelstein
Ph: 866-223-8100

David J. Adelstein
Principal Investigator

Mayfield Heights

Hillcrest Hospital Cancer Center

David J. Adelstein
Ph: 866-223-8100

David J. Adelstein
Principal Investigator

Medina

Summa Health Center at Lake Medina

Desiree E. Doncals
Ph: 330-375-6101

Desiree E. Doncals
Principal Investigator

Mentor

Lake University Ireland Cancer Center

Min Yao
Ph: 800-641-2422

Min Yao
Principal Investigator

Middleburg Heights

Southwest General Health Center Ireland Cancer Center

Min Yao
Ph: 800-641-2422

Min Yao
Principal Investigator

Oregon

Saint Charles Hospital

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

Parma

University Hospitals Parma Medical Center

Min Yao
Ph: 800-641-2422

Min Yao
Principal Investigator

Portsmouth

Southern Ohio Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Sandusky

Ireland Cancer Center at Firelands Regional Medical Center

Min Yao
Ph: 800-641-2422

Min Yao
Principal Investigator

North Coast Cancer Care

David J. Adelstein
Ph: 866-223-8100

David J. Adelstein
Principal Investigator

Strongsville

Cleveland Clinic Cancer Center Strongsville

David J. Adelstein
Ph: 866-223-8100

David J. Adelstein
Principal Investigator

Sylvania

Flower Hospital

Jeffrey Henry Muler
Ph: 419-824-1842

Jeffrey Henry Muler
Principal Investigator

Toledo

Mercy Saint Anne Hospital

Rex B. Mowat
Ph: 800-444-3561

Rex B. Mowat
Principal Investigator

West Chester

University Pointe

Kevin Patrick Redmond
Ph: 513-558-4553
Email: uchealthnews@uc.edu

Kevin Patrick Redmond
Principal Investigator

Westlake

UHHS-Westlake Medical Center

Min Yao
Ph: 800-641-2422

Min Yao
Principal Investigator

Wooster

Cleveland Clinic Wooster Family Health and Surgery Center

David J. Adelstein
Ph: 866-223-8100

David J. Adelstein
Principal Investigator

Oklahoma
Oklahoma City

University of Oklahoma Health Sciences Center

Terence S. Herman
Ph: 405-271-8777
Email: ou-clinical-trials@ouhsc.edu

Terence S. Herman
Principal Investigator

Oregon
Clackamas

Clackamas Radiation Oncology Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Eugene

Willamette Valley Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Portland

Portland Veterans Administration Medical Center

Daniel Robert Clayburgh
Ph: 503-494-1080
Email: trials@ohsu.edu

Daniel Robert Clayburgh
Principal Investigator

Providence Portland Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Providence Saint Vincent Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Pennsylvania
Danville

Geisinger Medical Center

Michael J. Greenberg
Ph: 570-271-5251
Email: mgreenberg@geisinger.edu

Michael J. Greenberg
Principal Investigator

Dunmore

Northeast Radiation Oncology Center

Rita S. Axelrod
Ph: 215-955-6084

Rita S. Axelrod
Principal Investigator

East Stroudsburg

Pocono Medical Center

Rita S. Axelrod
Ph: 215-955-6084

Rita S. Axelrod
Principal Investigator

Easton

Easton Hospital

Mariette Davies Austin
Ph: 610-250-4000

Mariette Davies Austin
Principal Investigator

Greensburg

UPMC Cancer Centers - Arnold Palmer Pavilion

Dwight Earl Heron
Ph: 412-647-8073

Dwight Earl Heron
Principal Investigator

Johnstown

UPMC-Johnstown/John P. Murtha Regional Cancer Center

Dwight Earl Heron
Ph: 412-647-8073

Dwight Earl Heron
Principal Investigator

McKeesport

UPMC Cancer Center at UPMC McKeesport

Dwight Earl Heron
Ph: 412-647-8073

Dwight Earl Heron
Principal Investigator

Philadelphia

Thomas Jefferson University Hospital

Rita S. Axelrod
Ph: 215-955-6084

Rita S. Axelrod
Principal Investigator

Pittsburgh

UPMC Jefferson Regional Radiation Oncology

Dwight Earl Heron
Ph: 412-647-8073

Dwight Earl Heron
Principal Investigator

UPMC-Passavant Hospital

Dwight Earl Heron
Ph: 412-647-8073

Dwight Earl Heron
Principal Investigator

UPMC-Saint Clair Hospital Cancer Center

Dwight Earl Heron
Ph: 412-647-8073

Dwight Earl Heron
Principal Investigator

UPMC-Saint Margaret

Dwight Earl Heron
Ph: 412-647-8073

Dwight Earl Heron
Principal Investigator

UPMC-Shadyside Hospital

Dwight Earl Heron
Ph: 412-647-8073

Dwight Earl Heron
Principal Investigator

Pottstown

Pottstown Memorial Medical Center

Wei (Frank) Song
Ph: 610-970-3145
Email: frank_song@chs.net

Wei (Frank) Song
Principal Investigator

Seneca

UPMC Cancer Center at UPMC Northwest

Dwight Earl Heron
Ph: 412-647-8073

Dwight Earl Heron
Principal Investigator

West Reading

Reading Hospital

Albert Yuen
Ph: 610-988-9323

Albert Yuen
Principal Investigator

South Carolina
Charleston

Medical University of South Carolina

Anand Kumar Sharma
Ph: 843-792-9321

Anand Kumar Sharma
Principal Investigator

Greenville

Greenville Health System Cancer Institute-Eastside

David Lawrence Grisell
Ph: 864-241-6251
Email: dgrisell@ghs.org

David Lawrence Grisell
Principal Investigator

Greenville Health System Cancer Institute-Faris

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Greer

Gibbs Cancer Center-Pelham

Patricia C. Griffin
Ph: 800-486-5941

Patricia C. Griffin
Principal Investigator

Greenville Health System Cancer Institute-Greer

David Lawrence Grisell
Ph: 864-241-6251
Email: dgrisell@ghs.org

David Lawrence Grisell
Principal Investigator

Seneca

Greenville Health System Cancer Institute-Seneca

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg

Greenville Health System Cancer Institute-Spartanburg

David Lawrence Grisell
Ph: 864-241-6251

David Lawrence Grisell
Principal Investigator

Spartanburg Medical Center

Patricia C. Griffin
Ph: 800-486-5941

Patricia C. Griffin
Principal Investigator

South Dakota
Rapid City

Rapid City Regional Hospital

Michael J. Swartz
Ph: 605-716-3982
Email: research@rcrh.org

Michael J. Swartz
Principal Investigator

Sioux Falls

Sanford Cancer Center-Oncology Clinic

Preston D. Steen
Ph: 701-234-6161

Preston D. Steen
Principal Investigator

Tennessee
Kingsport

Wellmont Holston Valley Hospital and Medical Center

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Texas
Austin

Texas Oncology - Central Austin Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Texas Oncology - South Austin Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Texas Oncology-Austin Midtown

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Dallas

UT Southwestern/Simmons Cancer Center-Dallas

Lucien Alexander Nedzi
Ph: 214-648-7097

Lucien Alexander Nedzi
Principal Investigator

Denton

Texas Oncology-Denton South

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Flower Mound

Texas Oncology-Flower Mound

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Fort Worth

The Klabzuba Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Houston

Ben Taub General Hospital

Mark David Bonnen
Ph: 713-798-1354
Email: burton@bcm.edu

Mark David Bonnen
Principal Investigator

M D Anderson Cancer Center

Erich Madison Sturgis
Ph: 713-794-4662
Email: esturgis@mdanderson.org

Erich Madison Sturgis
Principal Investigator

Memorial Hermann Memorial City Medical Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Plano

Texas Oncology-Plano West

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Round Rock

Texas Oncology - Round Rock Cancer Center

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Texas Oncology-Seton Williamson

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Sherman

Texas Cancer Center-Sherman

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Sugar Land

Texas Oncology Cancer Center Sugar Land

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Utah
Murray

Intermountain Medical Center

Vilija N. Avizonis
Ph: 801-507-3810
Email: vilija.avizonis@imail.org

Vilija N. Avizonis
Principal Investigator

Provo

Utah Valley Regional Medical Center

Vilija N. Avizonis
Ph: 801-507-3810
Email: vilija.avizonis@imail.org

Vilija N. Avizonis
Principal Investigator

Saint George

Dixie Medical Center Regional Cancer Center

Vilija N. Avizonis
Ph: 801-507-3810
Email: vilija.avizonis@imail.org

Vilija N. Avizonis
Principal Investigator

Salt Lake City

Huntsman Cancer Institute/University of Utah

Ying Jia Hitchcock
Ph: 801-581-3502
Email: clinical.trials@hci.utah.edu

Ying Jia Hitchcock
Principal Investigator

LDS Hospital

Vilija N. Avizonis
Ph: 801-507-3810
Email: vilija.avizonis@imail.org

Vilija N. Avizonis
Principal Investigator

Utah Cancer Specialists-Salt Lake City

Vilija N. Avizonis
Ph: 801-507-3810
Email: vilija.avizonis@imail.org

Vilija N. Avizonis
Principal Investigator

Virginia
Hampton

Sentara Cancer Institute at Sentara CarePlex Hospital

Scott S. Williams
Ph: 757-388-2406

Scott S. Williams
Principal Investigator

Norfolk

Sentara Hospitals

Scott S. Williams
Ph: 757-388-2406

Scott S. Williams
Principal Investigator

Washington
Kennewick

Tri-Cities Cancer Center

George E. Laramore
Ph: 206-598-3498
Email: georgel@uw.edu

George E. Laramore
Principal Investigator

Mount Vernon

Skagit Valley Hospital

George E. Laramore
Ph: 206-598-3498
Email: georgel@uw.edu

George E. Laramore
Principal Investigator

Seattle

University of Washington Medical Center

George E. Laramore
Ph: 206-598-3498
Email: georgel@uw.edu

George E. Laramore
Principal Investigator

Spokane

Cancer Care Northwest - Spokane South

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Cancer Care Northwest-North Spokane

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

Vancouver

Compass Oncology Vancouver

Vivek S. Kavadi
Ph: 281-277-5200

Vivek S. Kavadi
Principal Investigator

PeaceHealth Southwest Medical Center

Matthew C. Solhjem
Ph: 503-215-6412
Email: Julie.Cramer@providence.org

Matthew C. Solhjem
Principal Investigator

Wenatchee

Wenatchee Valley Hospital and Clinics

George E. Laramore
Ph: 206-598-3498
Email: georgel@uw.edu

George E. Laramore
Principal Investigator

West Virginia
Morgantown

West Virginia University Healthcare

Mohammed Almubarak
Ph: 304-293-2745
Email: sfilburn@hsc.wvu.edu

Mohammed Almubarak
Principal Investigator

Wheeling

Wheeling Hospital/Schiffler Cancer Center

Jondavid Pollock
Ph: 304-243-5047
Email: jpollock@wheelinghospital.org

Jondavid Pollock
Principal Investigator

Wisconsin
Antigo

Langlade Hospital and Cancer Center

Darryl Roderick Barton
Ph: 877-405-6866

Darryl Roderick Barton
Principal Investigator

Green Bay

Saint Vincent Hospital

Eva N. Christensen
Ph: 920-433-3168
Email: echristensen@gboncology.com

Eva N. Christensen
Principal Investigator

Madison

University of Wisconsin Hospital and Clinics

Paul Maurice Harari
Ph: 877-405-6866

Paul Maurice Harari
Principal Investigator

Marinette

Bay Area Medical Center

Eva N. Christensen
Ph: 920-433-3168
Email: echristensen@gboncology.com

Eva N. Christensen
Principal Investigator

Milwaukee

Zablocki Veterans Administration Medical Center

Elizabeth M. Gore
Ph: 414-805-4380
Email: egore@mcw.edu

Elizabeth M. Gore
Principal Investigator

Sturgeon Bay

Door County Cancer Center

Eva N. Christensen
Ph: 920-433-3168
Email: echristensen@gboncology.com

Eva N. Christensen
Principal Investigator

Wausau

Aspirus Regional Cancer Center

Darryl Roderick Barton
Ph: 877-405-6866

Darryl Roderick Barton
Principal Investigator

Wisconsin Rapids

Aspirus UW Cancer Center

Paul Maurice Harari
Ph: 877-405-6866

Paul Maurice Harari
Principal Investigator

Canada

Newfoundland and Labrador
St. John's

Doctor H. Bliss Murphy Cancer Centre

Craig Michael Pochini
Ph: 709-777-7589

Craig Michael Pochini
Principal Investigator

Ontario
Ottawa

Ottawa Hospital and Cancer Center-General Campus

Samy El-Sayed
Ph: 613-247-3511
Email: info@ohri.ca

Samy El-Sayed
Principal Investigator

Toronto

University Health Network-Princess Margaret Hospital

John (Joon-Hyung) Kim
Ph: 416-946-4501
Email: clinical.trials@uhn.on.ca

John (Joon-Hyung) Kim
Principal Investigator

China

Shatin

Chinese University of Hong Kong-Prince of Wales Hospital

Michael Koon Ming Kam
Ph: 852-2635-1408
Email: m_kam@clo.cuhk.edu.hk

Michael Koon Ming Kam
Principal Investigator

Saudi Arabia

Riyadh

King Faisal Specialist Hospital and Research Centre

Nasser M. Al-Rajhi
Ph: 011-966-1-464-7272-ext-38005
Email: nrajhi@kfshrc.edu.sa

Nasser M. Al-Rajhi
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT00956007

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.